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1682-606X/Copyright ª 2015, TaiwanAbstract Unplanned surgery of a soft tissue sarcoma is defined as the gross removal of a tu-
mor without appropriate preoperative imaging, biopsy, or attention to the wide surgical
margin. Referrals after unplanned surgery account for between 14.7% and 53% of new patients
in sarcoma centers. Treatment includes multiple modalities. It has been reported that 35e74%
of residual sarcomas are found in reexcised specimens. Therefore, additional reexcision is typi-
cally warranted to remove the residual tumor and obtain an adequately safe margin. Adjuvant
radiotherapy is generally used if the sarcoma is large, high grade, and deeply located. Adju-
vant chemotherapy remains controversial because of its marginal benefits. A recent study indi-
cated that adjuvant chemotherapy, an ifosfamide/epidoxorubicin protocol, showed 19%
improvement in overall survival at 4 years. Therefore, adjuvant chemotherapy should be
reserved for patients with a large, high-grade, localized lesion, and stage-IV disease. Un-
planned surgery of high-grade sarcomas has resulted in increased rates of local recurrence
but not disease-specific survival. Adequate additional reexcision may improve local control
and survival. To avoid unplanned surgery of soft tissue sarcomas, guidelines have been recom-
mended for clinicians to increase their awareness of the clinical features that suggest malig-
nancy in any soft tissue lump.
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Soft tissue sarcomas (STSs) are rare and heterogenic
primary malignant tumors. They originate from the
mesoderm and comprise < 1% of adult malignancies and
15% of all pediatric malignancies.1 Because of the rarity
of this disease, patients and physicians are often unaware
of the involved tumor, thus delaying diagnosis and initial
proper treatment. In addition, most general surgeons
may not be familiar with the advanced multidisciplinary
management. Therefore, hasty biopsy and unplanned
surgery before referral frequently complicate the sub-
sequent definite surgery and lead to a poor clinical
outcome.
Unplanned surgery is defined as an operation undertaken
for any excision of STSs without appropriate preoperative
imaging, biopsy, or attention to the wide surgical mar-
gin.2e4 Once unplanned surgery has been performed, the
margin of reexcision must to be more extensive than the
standard wide margin. This may necessitate soft tissue
reconstruction and result in a longer operation time, com-
plications, and functional loss.
Referrals after unplanned surgery account for between
14.7% and 53% of new patients in sarcoma centers.5e7 Even
if there is no gross evidence of disease from clinical ex-
amination or contrast-enhanced magnetic resonance im-
aging (MRI), 35e74% of residual sarcomas have been found
in the reexcised specimen.3,7e9 Reexcision is generally
warranted to remove the residual tumor or obtain an
adequately safe margin. Numerous reports have addressed
clinical problems that could occur after initial unplanned
excision.10,11 However, considerable controversy exists
regarding the criteria of reexcision and the sequencing of
radiation and surgery.
2. Inappropriately executed biopsy
Biopsy is the first step in the diagnosis of STSs. Without
appropriate planning, poorly performed biopsy or the
malposition of drainage often compromises the subsequent
local management of STSs. A transverse incision in the ex-
tremities, a common error for an unexperienced surgeon,
typically results in a more extensive excision or the need
for a flap reconstruction. Therefore, a transverse incision
for biopsy is absolutely contraindicated.
On the basis of biopsy diagnosis and definitive diag-
nosis, Mankin et al12 reported an error rate of 17.8% in
597 patients. Of these 106 erroneous diagnoses, 81 (76%)
were considered major errors and two-thirds occurred at
referring institutions. When the biopsy was performed in
a referring institute, the errors, complications, and
dismal results were from two to 12 times greater
compared with the biopsy performed in a sarcoma cen-
ter. In addition, a 16% unnecessary amputation rate and
10% mortality rate were attributed to the complications
of hasty biopsy. Therefore, although the biopsy is not a
technically demanding procedure, it should be per-
formed by the surgeon who will perform the definitive
excision for the patient. Moreover, adhering to certain
guidelines of the biopsy for extremity STSs is crucial
(Table 1).3. Evaluation after referral
Evaluating a referred patient consists of a physical exami-
nation, MRI of the tumor bed, computed tomography of the
chest to determine the presence of metastases, and a
complete review of the clinical data provided from the
referring surgeon. Moreover, the original histologic material
should be reviewed by an experienced musculoskeletal
pathologist to confirm the diagnosis of STS. Determining the
presence of a residual tumor after unplanned surgery re-
mains challenging. Noria et al3 reported a 42% residual
tumor rate in 65 patients who presented no gross evidence
of a tumor from physical examination or MRI. Moreover,
Manso et al7 reported that MRI may have a false-negative
rate of 25%. Chandrasekar et al6 suggested several clinical
parameters for determining the increased rates of a resid-
ual tumor, including tumors that are high grade, > 5 cm,
and deep to the fascia.
After multidisciplinary evaluation, a treatment program
is individually formulated with reexcision, adjuvant radio-
therapy (RT), or chemotherapy, and soft tissue recon-
struction if indicated.
4. Does unplanned surgery always require
reexcision?
The reported rate of reresection has varied from 35% to
100%, with the residual tumor rate ranging from 24% to
74%.2,3,5,9,13,14 According to the definition,2,3 for the pa-
tients presenting after unplanned surgery where margin is
uncertain or positive, reexcision is generally
recommended.10,11,15
RT alone without additional excision was occasionally
indicated in patients who were either medically inoper-
able or in whom further surgery would increase
morbidity. Bell et al reported a 50% local control (LC) rate
for patients who were received RT only without reexci-
sion following unplanned surgery. Zagars et al,16 371 of
666 patients who could not receive reexcision because of
various reasons underwent RT only at a total dosage of
60e70 Gy. The 15-year LC, disease-free survival, and
distant metastasis-free survival rates were 73%, 48%, and
64%, respectively. The results were less favorable
compared with the group that underwent reexcision with
postoperative RT.
Once unplanned surgery has been performed, the sur-
gical margin of reexcision must be more extensive than the
initial margin.17
5. Reexcision timing
The mean interval from the initial unplanned surgery to
reexcision varies from 36 days to 108 days.10,14,18 Delay of a
reexcision theoretically allows the proliferation of residual
tumor cells, thus increasing the likelihood of local recur-
rence. Patients’ delay was presumed to be one of the main
reasons.19 Patients are recommended to receive reexcision
as soon as possible, ideally within 3 weeks after the un-
planned surgery. However, delaying reexcision could
improve wound healing and prevent wound complications.
Table 1 Guidelines for incisional biopsy for extremity soft tissue sarcoma.
- For a small longitudinal incision, the biopsy tract should not transverse the normal musculoskeletal compartment or neu-
rovascular bundle.
- Transverse incisions are contraindicated.
- Avoid crushing or distorting the texture of the specimen.
- Obtain a frozen section to determine the adequacy of the specimen.
- Use meticulous hemostasis.
- Use drainage if necessary. The port of entry must be positioned in proximity to & along the planned incision of the definitive
surgery, not its sides.
- Close the wound carefully to prevent necrosis.
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capture the tumor cell and provide a more defined margin,
thus allowing more effective LC. Han et al19 reported that
any influence of delayed remargin surgery is likely to be of
minor clinical importance.206. Adjuvant radiotherapy and chemotherapy
RT would not be recommended for patients without a re-
sidual tumor after reexcision or for patients with a low-
grade STS with a negative margin.7 Adjuvant RT is generally
used if the sarcoma is large, high grade, and deeply
located. Most series have used at least selective adjuvant
therapy after reexcision for high-risk patients following
unplanned surgery.2,6,7,10,15 RT can be administrated prior
to, during, or following the reexcision. Regarding the
sequencing of RT and reexcision, substantial controversy
exists. The differences between preoperative RT and
postoperative RT are quality and the timing of toxicity. In
addition, preoperative RT has theoretical advantages such
as producing less radiation at a lower dosage, sterilizing the
reactive zone, avoiding tumor hypoxia, and reducing
radiosensitivity. However, increased wound complications
are a major concern in preoperative RT.1 Postoperative RT
does not interfere with the pathological evaluation of the
residual tumor and avoids increasing the risk of wound
complications. However, postoperative RT may result in
greater long-term toxicity including fibrosis, edema, bone
fracture, and functional impairment.21
Adjuvant chemotherapy remains controversial because
of its marginal benefits. A recent study indicated that
adjuvant chemotherapy, an ifosfamide/epidoxorubicin
protocol, showed 19% improvement in overall survival at 4
years.22 Therefore, adjuvant chemotherapy should be
reserved for patients with a large, high-grade, localized
lesion, and stage-IV disease.7Table 2 Red flag signs of soft tissue lumps.
- Mass size > 5 cm
- Rapid tumor growth
- Mass located deep to the fascia
- Painful lump7. Impact of unplanned surgery on prognosis
Several studies have investigated the disease-specific sur-
vival, metastasis, and local recurrence rates of patients
who underwent unplanned surgery of STSs. Variable out-
comes have been reported from several sarcoma centers.
Ueda et al22 found that the local recurrence rate was higher
in patients who received unplanned surgery than those who
received successful primary wide excision.23 Fiore et al14
analyzed 597 consecutive patients with primary STSs. Of
the 597 patients, 318 were referred after unplanned sur-
gery and the remaining 279 patients underwent primary
resection. The 10-year cumulative incidences in the reex-
cision and primary-operated groups were respectively
18.7% and 16.4% for local recurrence, 17.6% and 20.2% for
metastasis, and 20.4% and 22.4% for mortality. The
outcome of patients who underwent reexcision was similar
to that of patients who had primary resection.14 Hoshi
et al10 reported that the 5-year overall survival was 76.3%
and the outcomes were almost equivalent to those in pre-
vious reports. They addressed the significant role of wide
reexcision in improving the outcome of unplanned resection
compared with inadequate treatment without reexcision.10
Chandrasekar et al6 found that despite reexcision, the
risk of local recurrence remains high. The risk is doubled
when a residual tumor is present in reexcised specimens
and for high-grade tumors, marginal reexcision, and deep-
seated tumors.6
8. Conclusion
In contrast to other orthopedic fields, a disease encoun-
tered in musculoskeletal oncology could be life threat-
ening. Most soft tissue tumors are not malignant, and STSs
are often misdiagnosed clinically as benign lesions (e.g.,
lipoma, hematoma, and lymph nodes). The relatively
higher incidence rates of local recurrence and amputation
in the unplanned surgery group emphasizes the importance
of referrals and preventing iatrogenic mistakes such as
hasty biopsy and margin-positive primary resections. To
avoid unplanned surgery of STSs, guidelines for clinicians to
increase their awareness of the clinical features that sug-
gest malignancy in any soft tissue lump are recommended
(Table 2). The more clinical features are present, the
greater is the risk of malignancy.24 On excision of any soft
tissue tumor, surgeons should be aware of the potential risk
120 C.-F. Chen et al.of erroneous management of malignancy. Education and
standardization of the treatment for STSs are essential for
avoiding unplanned surgery.References
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